{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,29]],"date-time":"2026-10-29T16:07:34Z","timestamp":1793290054312,"version":"4.5.0"},"reference-count":23,"publisher":"American Medical Association (AMA)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Netw Open"],"abstract":"Importance<\/jats:title>Contemporary North American trials for children with Hodgkin lymphoma (HL) have decreased radiation therapy (RT) use and increased pharmacologic cardioprotection but also increased the cumulative doxorubicin dose, making overall treatment consequences for late cardiac toxic effects uncertain.<\/jats:p><\/jats:sec>Objective<\/jats:title>To estimate the risk of cardiac toxic effects associated with treatments used in modern pediatric HL clinical trials.<\/jats:p><\/jats:sec>Design, Setting, and Participants<\/jats:title>For this cohort study, Fine and Gray models were fitted using survivors in the Childhood Cancer Survivor Study who were diagnosed with HL between January 1, 1970, and December 31, 1999, and were followed for a median of 23.5 (range, 5.0-46.3) years. These models were applied to the exposures in the study population to estimate the 30-year cumulative incidence of cardiac disease. The study population comprised patients with intermediate-risk or high-risk HL treated in 4 consecutive Children\u2019s Oncology Group clinical trials from September 2002 to October 2022: AHOD0031, AHOD0831, AHOD1331, and S1826. Data analysis was performed from April 2020 to February 2023.<\/jats:p><\/jats:sec>Exposures<\/jats:title>All patients received chemotherapy including doxorubicin, and some patients received mediastinal RT, dexrazoxane, or mediastinal RT and dexrazoxane.<\/jats:p><\/jats:sec>Main Outcomes and Measures<\/jats:title>Estimated 30-year cumulative incidence of grade 3 to 5 cardiac disease.<\/jats:p><\/jats:sec>Results<\/jats:title>The study cohort comprised 2563 patients, with a median age at diagnosis of 15 (range, 1-22) years. More than half of the patients were male (1357 [52.9%]). All 2563 patients received doxorubicin, 1362 patients (53.1%) received mediastinal RT, and 307 patients (12.0%) received dexrazoxane. Radiation therapy use and the median mean heart dose among patients receiving RT decreased, whereas the planned cumulative dose of doxorubicin and use of dexrazoxane cardioprotection increased. For patients treated at age 15 years, the estimated 30-year cumulative incidence of severe or fatal cardiac disease was 9.6% (95% CI, 4.2%-16.4%) in the AHOD0031 standard treatment group (enrolled 2002-2009), 8.6% (95% CI, 3.8%-14.9%) in the AHOD0831 trial (enrolled 2009-2012), 8.2% (95% CI, 3.6%-14.3%) in the AHOD1331 trial (enrolled 2015-2019), and 6.2% (95% CI, 2.7%-10.9%) in the S1826 trial (enrolled 2019-2022), whereas the expected rate in an untreated population was 5.0% (95% CI, 2.1%-9.3%). Despite the estimated reduction in late cardiac morbidity, the frequency of recommended echocardiographic screening among survivors will increase based on current guidelines.<\/jats:p><\/jats:sec>Conclusions and Relevance<\/jats:title>In this cohort study of sequential HL trials, reductions in the proportion of children receiving mediastinal RT and increases in dexrazoxane use were estimated to offset the increased doxorubicin dose and produce a net reduction in late cardiac disease. Further studies on dexrazoxane are warranted to confirm whether its role in reducing cardiac toxic effects is maintained long term. These findings suggest that survivorship follow-up guidelines should be refined to align with the risks associated with treatment.<\/jats:p><\/jats:sec>","DOI":"10.1001\/jamanetworkopen.2023.51062","type":"journal-article","created":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:31:12Z","timestamp":1705681872000},"page":"e2351062","source":"Crossref","is-referenced-by-count":22,"title":["Late Cardiac Toxic Effects Associated With Treatment Protocols for Hodgkin Lymphoma in Children"],"prefix":"10.1001","volume":"7","author":[{"given":"Andrea C.","family":"Lo","sequence":"first","affiliation":[{"name":"Department of Radiation Oncology, BC Cancer, University of British Columbia, Vancouver, British Columbia, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Liu","sequence":"additional","affiliation":[{"name":"Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qi","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Public Health Sciences, University of Alberta, Edmonton, Alberta, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Yasui","sequence":"additional","affiliation":[{"name":"Epidemiology and Cancer Control Department, St Jude Children\u2019s Research Hospital, Memphis, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon M.","family":"Castellino","sequence":"additional","affiliation":[{"name":"Aflac Cancer and Blood Disorders Center, Children\u2019s Healthcare of Atlanta, Atlanta, Georgia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kara M.","family":"Kelly","sequence":"additional","affiliation":[{"name":"Department of Pediatric Oncology, Roswell Park Cancer Institute and Oishei Children\u2019s Hospital, University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex F.","family":"Hererra","sequence":"additional","affiliation":[{"name":"Department of Hematology, City of Hope, Duarte, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan W.","family":"Friedberg","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debra L.","family":"Friedman","sequence":"additional","affiliation":[{"name":"Division of Pediatric Hematology\/Oncology, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Nashville, Tennessee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cindy L.","family":"Schwartz","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Children\u2019s Hospital of Wisconsin, Medical College of Wisconsin, Milwaukee"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglin","family":"Pei","sequence":"additional","affiliation":[{"name":"Children\u2019s Oncology Group, Statistics and Data Center, Department of Biostatistics, University of Florida, Gainesville"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandy","family":"Kessel","sequence":"additional","affiliation":[{"name":"Imaging and Radiation Oncology Core, Lincoln, Rhode Island"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Bergeron-Gravel","sequence":"additional","affiliation":[{"name":"Centre Hospitalier Universitaire de Qu\u00e9bec\u2013Universit\u00e9 Laval, Qu\u00e9bec, Quebec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hitesh","family":"Dama","sequence":"additional","affiliation":[{"name":"Princess Margaret Cancer Centre, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenneth","family":"Roberts","sequence":"additional","affiliation":[{"name":"Therapeutic Radiology, Yale University School of Medicine, New Haven, Connecticut"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis S.","family":"Constine","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Wilmot Cancer Institute, University of Rochester, Rochester, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Princess Margaret Cancer Centre\u2013University Health Network, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","published-online":{"date-parts":[[2024,1,19]]},"reference":[{"issue":"1","key":"zoi231497r1","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1182\/asheducation-2016.1.323","article-title":"Long-term risk of second malignancy and cardiovascular disease after Hodgkin lymphoma treatment.","volume":"2016","author":"van Leeuwen","year":"2016","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"zoi231497r2","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1001\/jamainternmed.2015.1180","article-title":"Cardiovascular disease after Hodgkin lymphoma treatment: 40-year disease risk.","volume":"175","author":"van Nimwegen","year":"2015","journal-title":"JAMA Intern Med"},{"issue":"8","key":"zoi231497r3","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1200\/JCO.2008.20.2267","article-title":"Role of cancer treatment in long-term overall and cardiovascular mortality after childhood cancer.","volume":"28","author":"Tukenova","year":"2010","journal-title":"J Clin Oncol"},{"issue":"29","key":"zoi231497r4","doi-asserted-by":"publisher","first-page":"3673","DOI":"10.1200\/JCO.2013.49.3205","article-title":"Modifiable risk factors and major cardiac events among adult survivors of childhood cancer.","volume":"31","author":"Armstrong","year":"2013","journal-title":"J Clin Oncol"},{"issue":"13","key":"zoi231497r5","doi-asserted-by":"publisher","first-page":"1090","DOI":"10.1200\/JCO.18.01764","article-title":"Therapy-related cardiac risk in childhood cancer survivors: an analysis of the Childhood Cancer Survivor Study.","volume":"37","author":"Bates","year":"2019","journal-title":"J Clin Oncol"},{"key":"zoi231497r6","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.radonc.2020.10.017","article-title":"Development and validation of an age-scalable cardiac model with substructures for dosimetry in late-effects studies of childhood cancer survivors.","volume":"153","author":"Shrestha","year":"2020","journal-title":"Radiother Oncol"},{"issue":"20","key":"zoi231497r7","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","article-title":"World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects.","volume":"310","author":"World Medical Association","year":"2013","journal-title":"JAMA"},{"issue":"32","key":"zoi231497r8","doi-asserted-by":"publisher","first-page":"3651","DOI":"10.1200\/JCO.2013.52.5410","article-title":"Dose-intensive response-based chemotherapy and radiation therapy for children and adolescents with newly diagnosed intermediate-risk Hodgkin lymphoma: a report from the Children\u2019s Oncology Group Study AHOD0031.","volume":"32","author":"Friedman","year":"2014","journal-title":"J Clin Oncol"},{"issue":"1","key":"zoi231497r9","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/bjh.v187.1","article-title":"Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children\u2019s Oncology Group.","volume":"187","author":"Kelly","year":"2019","journal-title":"Br J Haematol"},{"issue":"18","key":"zoi231497r10","doi-asserted-by":"publisher","first-page":"1649","DOI":"10.1056\/NEJMoa2206660","article-title":"Brentuximab vedotin with chemotherapy in pediatric high-risk Hodgkin\u2019s lymphoma.","volume":"387","author":"Castellino","year":"2022","journal-title":"N Engl J Med"},{"issue":"14","key":"zoi231497r11","doi-asserted-by":"publisher","first-page":"2308","DOI":"10.1200\/JCO.2009.22.3339","article-title":"The Childhood Cancer Survivor Study: a National Cancer Institute-supported resource for outcome and intervention research.","volume":"27","author":"Robison","year":"2009","journal-title":"J Clin Oncol"},{"issue":"4","key":"zoi231497r14","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv357","article-title":"Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and meta-analysis.","volume":"108","author":"Shaikh","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"zoi231497r16","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.17_suppl.LBA4","article-title":"SWOG1826, a randomized study of nivolumab (N)-AVD versus brentuximab vedotin (BV)-AVD in advanced stage (AS) classic Hodgkin lymphoma (HL).","volume":"41","author":"Herrera","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10","key":"zoi231497r17","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","article-title":"Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial.","volume":"11","author":"Lipshultz","year":"2010","journal-title":"Lancet Oncol"},{"issue":"12","key":"zoi231497r18","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","article-title":"Anthracyclines and heart failure.","volume":"368","author":"Sawyer","year":"2013","journal-title":"N Engl J Med"},{"issue":"4","key":"zoi231497r19","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1002\/cncr.v128.4","article-title":"Late health outcomes after dexrazoxane treatment: a report from the Children\u2019s Oncology Group.","volume":"128","author":"Chow","year":"2022","journal-title":"Cancer"},{"issue":"12","key":"zoi231497r20","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.22.02423","article-title":"Dexrazoxane and long-term heart function in survivors of childhood cancer.","volume":"41","author":"Chow","year":"2023","journal-title":"J Clin Oncol"},{"issue":"6","key":"zoi231497r21","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1002\/pbc.v55:6","article-title":"Late valvular and other cardiac diseases after different doses of mediastinal radiotherapy for Hodgkin disease in children and adolescents: report from the longitudinal GPOH follow-up project of the German-Austrian DAL-HD studies.","volume":"55","author":"Schellong","year":"2010","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"zoi231497r22","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1161\/CIRCULATIONAHA.115.016686","article-title":"Cardiac diseases following childhood cancer treatment: cohort study.","volume":"133","author":"Haddy","year":"2016","journal-title":"Circulation"},{"key":"zoi231497r23","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jare.2020.09.006","article-title":"PD-1\/PDL-1 inhibitors and cardiotoxicity; molecular, etiological and management outlines.","volume":"29","author":"Safi","year":"2020","journal-title":"J Adv Res"},{"key":"zoi231497r12","unstructured":"NRG Oncology. RADCOMP breast atlas. August 31, 2022. Accessed August 31, 2022. https:\/\/www.nrgoncology.org"},{"key":"zoi231497r13","unstructured":"Surveillance, Epidemiology, and End Results Program. SEER*Stat database: incidence\u2014SEER 18 regs research data + Hurricane Katrina impacted Louisiana cases, Nov 2018 Sub (1975-2016 Varying)\u2014linked to county attributes\u2014total U.S., 1969-2017 counties, National Cancer Institute, DCCPS, Surveillance Research Program. Released April 2019, based on the November 2018 submission. 2022. Accessed March 1, 2023. https:\/\/www.seer.cancer.gov"},{"key":"zoi231497r15","unstructured":"Children\u2019s Oncology Group. Long-term follow-up guidelines for survivors of childhood, adolescent, and young adult cancers. October 6, 2018. Accessed May 27, 2023. https:\/\/childrensoncologygroup.org\/survivorshipguidelines"}],"container-title":["JAMA Network Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/articlepdf\/2814093\/lo_2024_oi_231497_1704921084.80812.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,19]],"date-time":"2024-01-19T16:31:15Z","timestamp":1705681875000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamanetworkopen\/fullarticle\/2814093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1,19]]},"references-count":23,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1,2]]}},"URL":"https:\/\/doi.org\/10.1001\/jamanetworkopen.2023.51062","relation":{},"ISSN":["2574-3805"],"issn-type":[{"value":"2574-3805","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1,19]]}}}